I-Mab Founder Retakes Reins in Latest Shakeup Ahead of Commercialization Phase
Drug maker announces latest senior appointments as investors anticipate regulatory approval for some of its products as early as 2023 Key takeaways Four-year company veteran and CEO Joan Shen to…
RELATED ARTICLES
-
I-Mab gets new CEO after long search. Sale of the company coming next?
IMAB.US
-
Up in smoke? Not exactly for Huabao, crown jewel of China’s ‘vaping queen’
0336.HK 300741.SHE
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Xiao-I tries to generate buzz in crowded China AI field
AIXI.US
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Everest reaches new heights on growing drug sales
1952.HK
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
Discover hidden China stock gems in our weekly newsletter